NetworkNewsBreaks Archive - Page 2033 of 2178

WednesdaySep 27, 2017 12:34 pm

NetworkNewsBreaks – Mizuho: ViewRay, Inc. (NASDAQ: VRAY) Technology Topic of Discussion in Upcoming Industry Expert Conference Call

ViewRay (NASDAQ: VRAY) was recently covered in a U.S. Equity Research report by Mizuho Securities USA LLC. The company was issued a 'Buy' rating and price target of $12 per share. The company's technology will be part of an "Industry Expert Conference Call" taking place October 17 at 11 a.m. ET. The call will discuss "MRI guided LINAC – ViewRay’s MRidian or Elekta’s Unity?” Among others, a few topics to be covered include why MRI-LINAC is needed for radiation oncology, the decision-making process at Washington University in choosing ViewRay’s MRIdian and other relevant clinical experience. To view the full report,…

WednesdaySep 27, 2017 12:03 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Net Element, Inc. (NASDAQ: NETE)

SeeThruEquity updated coverage on Net Element, Inc. (NASDAQ: NETE) this week following release of the company’s earnings report for the second quarter of 2017. Net Element reported second quarter revenue of $16.1 million, representing an 18% increase from the second quarter of 2016. The analyst noted that this impressive performance was primarily attributed to the company’s NA Transactions segment, which saw revenue growth of 31% YoY. The company’s Online Solutions segment also displayed hearty growth from a small base with a revenue increase of 33% YoY. Additionally, the analyst noted that the company has been given until October 20, 2017,…

WednesdaySep 27, 2017 12:00 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Heron Therapeutics, Inc. (NASDAQ: HRTX)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The company currently has two drugs in development in the chemotherapy-induced nausea and vomiting (CINV) space. Its lead product, Sustol, is in the commercial stage, while Cinvanti is up for approval in November 2017. Heron expects to launch Cinvanti in the first quarter of 2018. The analyst believes that the company’s potential to have two CINV drugs targeting two sides of a $900 million market is underappreciated and predicts that Heron will reach break-even in…

WednesdaySep 27, 2017 11:59 am

NetworkNewsBreaks – Nektar Therapeutics (NASDAQ: NKTR) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $30 on shares of Nektar Therapeutics’ (NASDAQ: NKTR) stock. Mizuho analysts believe Nektar’s immuno-oncology candidate NKTR-214 is the company’s most valuable asset, as it could provide significant upside while the company’s royalty-generating portfolio maintains a more consistent revenue stream for the biotech company. Additionally, Nektar has formed collaborations with numerous pharmaceutical companies on its PEGylation platform, which also provides a predictable revenue stream and a stable foundation. For more information, visit www.Nektar.com About Nektar Nektar Therapeutics is a research-based development stage biopharmaceutical company with a…

WednesdaySep 27, 2017 9:30 am

NetworkNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Announces Acquisition of PotSaver

Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”), has finalized a majority ownership acquisition of PotSaver, a revenue-producing community periodical providing listings on discounted cannabis-related products for Southern California dispensaries and shops. Per this morning’s update, the majority ownership acquisition is expected to provide MTRAC with an immediate revenue stream related to PotSaver’s existing subscription-based earnings. “The majority ownership acquisition of PotSaver marks a significant milestone for MoneyTrac Technology,” Vanessa Luna, COO of MTRAC, stated in the news release. “Not only does it provide our company with an…

TuesdaySep 26, 2017 3:36 pm

NetworkNewsBreaks – Pivot Pharmaceuticals (PVOTF) and Solmic Research GmbH Sign License and Collaboration Agreement for Improved Oral Formulations of Cannabinoids

Pivot Pharmaceuticals (OTCQB: PVOTF) and its medical cannabis product division, Pivot Green Stream Health Solutions, recently announced the signing of a definitive agreement with Solmic Research GmbH (Germany) which gives Pivot Pharmaceuticals worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts. Solmic’s proprietary technology provides higher bioavailability and stability compared to alternative oil-based formulations. Solmic’s technology allows active ingredients to become water soluble without changing their composition and nature. To view the full article, visit http://nnw.fm/0IFyu About Pivot Pharmaceuticals Inc. Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company…

TuesdaySep 26, 2017 12:54 pm

NetworkNewsBreaks – ORHub, Inc. (ORHB) Retains Auditing Service ahead of Planned Uplisting

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced that it has retained an auditing service to fulfill the two-year audit necessary to become a fully reporting OTCQB-listed company. This move serves as part of ORHub’s long-term strategy of uplisting to the Nasdaq Capital Market in order to accelerate growth, transparency and market fortification. “We continue to see increases in customer activity and overall business progress, and it is now time for ORHub to advance to the more notable OTCQB tier,” Colt Melby, CEO of ORHub, stated in the news release. “We are pleased to announce that we are…

TuesdaySep 26, 2017 12:28 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on September 26, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MYSZ 33.11% – News: Receives its first patent CDNA 28.63% – News: MolDX program sets AlloSure reimbursement at 2017 AlloMap level MBRX 16.37% – News: Obtains approval for Annamycin IND from FDA ITUS 14.29% – News: Posts presentation from annual meeting of stockholders online TNTR 9.39% – News: Names new VP of channel sales PSSR 9.09% – News: Partners with Air France to develop PITM in Europe VERU 6.83% – News: Posts update regarding…

TuesdaySep 26, 2017 12:26 pm

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock following a meeting the company held in San Diego on Monday during the annual meeting of the American Society for Radiation Oncology (ASTRO). The analyst noted that ViewRay reaffirmed its 2017 full-year revenue guidance of $45-50 million. The affirmation by the company reassures the analyst’s prediction that the company is on track to possibly reach break-even by the end of 2018. During the meeting, the company also provided an update regarding the MRIdian. Among other highlights, the data…

TuesdaySep 26, 2017 11:01 am

NetworkNewsBreaks – AppSwarm, Inc. (SWRM) Announces Development of Last-Mile Delivery App

Technology development and incubation acceleration company AppSwarm, Inc. (OTC: SWRM) this morning announced the in-house development of its proprietary “last-mile” delivery app platform aimed at improving the efficiency of parcel delivery. “We are very excited to be completing this proprietary platform that creates much more efficient operations and management support,” Ron Brewer, CEO of AppSwarm, stated in the news release. “The 'last-mile' sector is growing at a pace that is nearly incomprehensible and we are focused on offering solutions that make growth in this sector easier and more efficient thru multiple technology platforms for businesses looking to solve very complicated…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks